Abivax announces a change in its governance

DGAP-News: ABIVAX / Key word(s): Staff

Abivax announces a change in its governance
16.08.2022 / 21:10 CET/EST
The issuer is solely responsible for the content of this announcement.

ABIVAX ANNOUNCES A CHANGE IN ITS GOVERNANCE

PARIS, France, August 16, 2022 – 9:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 biotechnology company developing novel immune-modulating therapies to treat chronic inflammatory diseases, viral infections and cancer, today announces a transition in the governance of its Board of Directors Directors.

Dr. Philippe Pouletty, MD, founder of Abivax and Chairman of the Board of Directors since the company’s inception in 2013, notified the Board of his intention to focus and allocate more time to other projects, including including companies listed on the stock exchange, and therefore to no longer assume the responsibilities of Chairman. Accordingly, Dr. Pouletty further notified the Board of his decision to resign as Chairman, effective immediately. Dr. Pouletty will however continue, after many years of successful leadership on the Board, to support the development of Abivax as a member of the Board.

Dr Pouletty said: “I am proud that Abivax is today one of the few European biotechnology companies to have a drug candidate, obefazimod (ABX464), entering phase 3 that addresses major medical needs in chronic inflammatory diseases. . Translating the radical innovation of great academic science into products that benefit patients has always been my goal. I am confident that Abivax will continue successfully under the new management.

Until a new permanent independent chairman is appointed, Ms. Corinna zur Bonsen-Thomas, currently an independent member of the board of directors, assumes the role of interim chairman of Abivax.

Ms. zur Bonsen-Thomas has over 30 years of leadership experience and has held various VP positions in the global pharmaceutical and medical device industry as well as digital health startups. She is co-founder and CEO of RetInSight, a digital health company, and has over 15 years of experience as a member of the supervisory board. Ms. zur Bonsen-Thomas has been a member of the Abivax Board of Directors since 2017.

“We respect Dr. Pouletty’s decision and thank him for his many contributions to the company over the past few years. Together with management, the board now looks forward to the change in governance under the new management. » said Ms. zur Bonsen-Thomas, President of Abivax.

*****

About Abivax (www.abivax.com)

Abivax, a clinical-stage Phase 3 biotechnology company, develops novel therapies that modulate the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Ticker: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information about the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

contacts

DISCLAIMER

This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) regarding some of the Company’s programs.. Although Abivax’s management believes that the expectations reflected in these forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, hazards and uncertaintiesmany of which are difficult to predict and generally beyond Abivax’s control, which could cause actual results and developments to differ materially from those expressed, implied or projected by the forward-looking information and statements. A description of these risks, contingencies and uncertainties appears in the documents filed by the Company with the Autorité des Marchés Financiers in application of its legal obligations, in particular its Universal Registration Document. These risks, contingencies and uncertainties include, among others, uncertainties inherent in research and development, future clinical data and analyses, decisions of regulatory authorities, such as the FDA or EMA, regarding whether and when to approve a drug, as well as their decisions regarding labeling and other matters that may affect the availability or commercial potential of these product candidates. Particular attention should be given to potential barriers to clinical and pharmaceutical development, including further evaluation by society and regulatory agencies and ethics/IRB boards following evaluation of preclinical, pharmacokinetic, carcinogenicity data , toxicity, CMC and clinical. Further, such forward-looking statements, forecasts and estimates speak only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update any such forward-looking statements, forecasts or estimates to reflect any subsequent changes of which the Company becomes aware, except as required by law. Information about pharmaceutical products (including products under development) that is included in this press release is not intended to constitute advertising. This press release is for informational purposes only and the information it contains does not constitute an offer to sell, nor the solicitation of an offer to buy or subscribe for securities of the Company in any jurisdiction whatsoever, in particular in France. Likewise, it does not and should not be considered as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be considered by recipients as a substitute for the exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons in possession of this document are required to inform themselves about and observe these restrictions.


16.08.2022 CET/CEST Dissemination of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.dgap.de


Comments are closed.